5-HT2A receptor blockade and 5-HT2C receptor activation interact to reduce cocaine hyperlocomotion and fos protein expression in the caudate-putamen

Lara A. Pockros, Nathan S. Pentkowski, Sineadh M. Conway, Teresa E. Ullman, Kimberly R. Zwick, Janet Neisewander

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Both the 5-HT2A receptor (R) antagonist M100907 and the 5-HT2CR agonist MK212 attenuate cocaine-induced dopamine release and hyperlocomotion. This study examined whether these drugs interact to reduce cocaine hyperlocomotion and Fos expression in the striatum and prefrontal cortex. We first determined from dose-effect functions a low dose of both M100907 and MK212 that failed to alter cocaine (15 mg/kg, i.p.) hyperlocomotion. Subsequently, we examined whether these subthreshold doses given together would attenuate cocaine hyperlocomotion, consistent with a 5-HT2A/5-HT2CR interaction. Separate groups of rats received two sequential drug injections 5 min apart immediately before a 1-h locomotion test as follows: (1) saline + saline, (2) saline + cocaine, (3) 0.025 mg/kg M100907 + cocaine, (4) 0.125 mg/kg MK212 + cocaine, or (5) cocktail combination of 0.025 mg/kg M100907 and 0.125 mg/kg MK212 + cocaine. Brains were extracted for Fos immunohistochemistry 90 min after the second injection. We next examined the effects of 0.025 mg/kg M100907 and 0.125 mg/kg MK212, alone and in combination, on spontaneous locomotor activity. While neither drug given alone produced any effects, the M100907/MK212 cocktail attenuated cocaine hyperlocomotion as well as cocaine-induced Fos expression in the dorsolateral caudate-putamen (CPu), but had no effect on spontaneous locomotion. The findings suggest that 5-HT2ARs and 5-HT2CRs interact to attenuate cocaine hyperlocomotion and Fos expression in the CPu, and that the CPu is a potential locus of the interactive effects between these 5-HT2R subtypes on behavior. Further research investigating combined 5-HT2AR antagonism and 5-HT2CR agonism as a treatment for cocaine dependence is warranted.

Original languageEnglish (US)
Pages (from-to)989-1001
Number of pages13
JournalSynapse
Volume66
Issue number12
DOIs
StatePublished - Dec 2012

Fingerprint

Receptor, Serotonin, 5-HT2C
Receptor, Serotonin, 5-HT2A
Putamen
Cocaine
Proteins
Locomotion
Pharmaceutical Preparations
Cocaine-Related Disorders
Injections
Prefrontal Cortex
MDL 100907
Dopamine

Keywords

  • Cocaine
  • Locomotion
  • M100907
  • MK212
  • Serotonin

ASJC Scopus subject areas

  • Cellular and Molecular Neuroscience

Cite this

5-HT2A receptor blockade and 5-HT2C receptor activation interact to reduce cocaine hyperlocomotion and fos protein expression in the caudate-putamen. / Pockros, Lara A.; Pentkowski, Nathan S.; Conway, Sineadh M.; Ullman, Teresa E.; Zwick, Kimberly R.; Neisewander, Janet.

In: Synapse, Vol. 66, No. 12, 12.2012, p. 989-1001.

Research output: Contribution to journalArticle

Pockros, Lara A. ; Pentkowski, Nathan S. ; Conway, Sineadh M. ; Ullman, Teresa E. ; Zwick, Kimberly R. ; Neisewander, Janet. / 5-HT2A receptor blockade and 5-HT2C receptor activation interact to reduce cocaine hyperlocomotion and fos protein expression in the caudate-putamen. In: Synapse. 2012 ; Vol. 66, No. 12. pp. 989-1001.
@article{2158c50bfaee4f71b1bcf253649601d0,
title = "5-HT2A receptor blockade and 5-HT2C receptor activation interact to reduce cocaine hyperlocomotion and fos protein expression in the caudate-putamen",
abstract = "Both the 5-HT2A receptor (R) antagonist M100907 and the 5-HT2CR agonist MK212 attenuate cocaine-induced dopamine release and hyperlocomotion. This study examined whether these drugs interact to reduce cocaine hyperlocomotion and Fos expression in the striatum and prefrontal cortex. We first determined from dose-effect functions a low dose of both M100907 and MK212 that failed to alter cocaine (15 mg/kg, i.p.) hyperlocomotion. Subsequently, we examined whether these subthreshold doses given together would attenuate cocaine hyperlocomotion, consistent with a 5-HT2A/5-HT2CR interaction. Separate groups of rats received two sequential drug injections 5 min apart immediately before a 1-h locomotion test as follows: (1) saline + saline, (2) saline + cocaine, (3) 0.025 mg/kg M100907 + cocaine, (4) 0.125 mg/kg MK212 + cocaine, or (5) cocktail combination of 0.025 mg/kg M100907 and 0.125 mg/kg MK212 + cocaine. Brains were extracted for Fos immunohistochemistry 90 min after the second injection. We next examined the effects of 0.025 mg/kg M100907 and 0.125 mg/kg MK212, alone and in combination, on spontaneous locomotor activity. While neither drug given alone produced any effects, the M100907/MK212 cocktail attenuated cocaine hyperlocomotion as well as cocaine-induced Fos expression in the dorsolateral caudate-putamen (CPu), but had no effect on spontaneous locomotion. The findings suggest that 5-HT2ARs and 5-HT2CRs interact to attenuate cocaine hyperlocomotion and Fos expression in the CPu, and that the CPu is a potential locus of the interactive effects between these 5-HT2R subtypes on behavior. Further research investigating combined 5-HT2AR antagonism and 5-HT2CR agonism as a treatment for cocaine dependence is warranted.",
keywords = "Cocaine, Locomotion, M100907, MK212, Serotonin",
author = "Pockros, {Lara A.} and Pentkowski, {Nathan S.} and Conway, {Sineadh M.} and Ullman, {Teresa E.} and Zwick, {Kimberly R.} and Janet Neisewander",
year = "2012",
month = "12",
doi = "10.1002/syn.21592",
language = "English (US)",
volume = "66",
pages = "989--1001",
journal = "Synapse",
issn = "0887-4476",
publisher = "Wiley-Liss Inc.",
number = "12",

}

TY - JOUR

T1 - 5-HT2A receptor blockade and 5-HT2C receptor activation interact to reduce cocaine hyperlocomotion and fos protein expression in the caudate-putamen

AU - Pockros, Lara A.

AU - Pentkowski, Nathan S.

AU - Conway, Sineadh M.

AU - Ullman, Teresa E.

AU - Zwick, Kimberly R.

AU - Neisewander, Janet

PY - 2012/12

Y1 - 2012/12

N2 - Both the 5-HT2A receptor (R) antagonist M100907 and the 5-HT2CR agonist MK212 attenuate cocaine-induced dopamine release and hyperlocomotion. This study examined whether these drugs interact to reduce cocaine hyperlocomotion and Fos expression in the striatum and prefrontal cortex. We first determined from dose-effect functions a low dose of both M100907 and MK212 that failed to alter cocaine (15 mg/kg, i.p.) hyperlocomotion. Subsequently, we examined whether these subthreshold doses given together would attenuate cocaine hyperlocomotion, consistent with a 5-HT2A/5-HT2CR interaction. Separate groups of rats received two sequential drug injections 5 min apart immediately before a 1-h locomotion test as follows: (1) saline + saline, (2) saline + cocaine, (3) 0.025 mg/kg M100907 + cocaine, (4) 0.125 mg/kg MK212 + cocaine, or (5) cocktail combination of 0.025 mg/kg M100907 and 0.125 mg/kg MK212 + cocaine. Brains were extracted for Fos immunohistochemistry 90 min after the second injection. We next examined the effects of 0.025 mg/kg M100907 and 0.125 mg/kg MK212, alone and in combination, on spontaneous locomotor activity. While neither drug given alone produced any effects, the M100907/MK212 cocktail attenuated cocaine hyperlocomotion as well as cocaine-induced Fos expression in the dorsolateral caudate-putamen (CPu), but had no effect on spontaneous locomotion. The findings suggest that 5-HT2ARs and 5-HT2CRs interact to attenuate cocaine hyperlocomotion and Fos expression in the CPu, and that the CPu is a potential locus of the interactive effects between these 5-HT2R subtypes on behavior. Further research investigating combined 5-HT2AR antagonism and 5-HT2CR agonism as a treatment for cocaine dependence is warranted.

AB - Both the 5-HT2A receptor (R) antagonist M100907 and the 5-HT2CR agonist MK212 attenuate cocaine-induced dopamine release and hyperlocomotion. This study examined whether these drugs interact to reduce cocaine hyperlocomotion and Fos expression in the striatum and prefrontal cortex. We first determined from dose-effect functions a low dose of both M100907 and MK212 that failed to alter cocaine (15 mg/kg, i.p.) hyperlocomotion. Subsequently, we examined whether these subthreshold doses given together would attenuate cocaine hyperlocomotion, consistent with a 5-HT2A/5-HT2CR interaction. Separate groups of rats received two sequential drug injections 5 min apart immediately before a 1-h locomotion test as follows: (1) saline + saline, (2) saline + cocaine, (3) 0.025 mg/kg M100907 + cocaine, (4) 0.125 mg/kg MK212 + cocaine, or (5) cocktail combination of 0.025 mg/kg M100907 and 0.125 mg/kg MK212 + cocaine. Brains were extracted for Fos immunohistochemistry 90 min after the second injection. We next examined the effects of 0.025 mg/kg M100907 and 0.125 mg/kg MK212, alone and in combination, on spontaneous locomotor activity. While neither drug given alone produced any effects, the M100907/MK212 cocktail attenuated cocaine hyperlocomotion as well as cocaine-induced Fos expression in the dorsolateral caudate-putamen (CPu), but had no effect on spontaneous locomotion. The findings suggest that 5-HT2ARs and 5-HT2CRs interact to attenuate cocaine hyperlocomotion and Fos expression in the CPu, and that the CPu is a potential locus of the interactive effects between these 5-HT2R subtypes on behavior. Further research investigating combined 5-HT2AR antagonism and 5-HT2CR agonism as a treatment for cocaine dependence is warranted.

KW - Cocaine

KW - Locomotion

KW - M100907

KW - MK212

KW - Serotonin

UR - http://www.scopus.com/inward/record.url?scp=84867634892&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84867634892&partnerID=8YFLogxK

U2 - 10.1002/syn.21592

DO - 10.1002/syn.21592

M3 - Article

C2 - 22886755

AN - SCOPUS:84867634892

VL - 66

SP - 989

EP - 1001

JO - Synapse

JF - Synapse

SN - 0887-4476

IS - 12

ER -